{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:17:07Z","timestamp":1793132227061,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jaad.2016.01.062","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T00:21:03Z","timestamp":1481674863000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"title":["Prevention and management of glucocorticoid-induced side effects: A comprehensive review"],"prefix":"10.1016","volume":"76","author":[{"given":"Avrom","family":"Caplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.01.062_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jaad.2016.01.062_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00302665","article-title":"Relative glucocorticoid potency revisited","volume":"14","author":"Tanaka","year":"1994","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaad.2016.01.062_bib3","series-title":"Principles and practice of endocrinology and metabolism","first-page":"751","article-title":"Corticosteroid therapy","author":"Axelrod","year":"2001"},{"key":"10.1016\/j.jaad.2016.01.062_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00005792-197601000-00003","article-title":"Glucocorticoid therapy","volume":"55","author":"Axelrod","year":"1976","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2016.01.062_bib5","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(71)92738-3","article-title":"Prednisone side-effects and serum-protein levels. A collaborative study","volume":"2","author":"Lewis","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2016.01.062_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2165\/00003088-199019020-00003","article-title":"Clinical pharmacokinetics of prednisone and prednisolone","volume":"19","author":"Frey","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jaad.2016.01.062_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1210\/jcem-38-3-407","article-title":"Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects","volume":"38","author":"Kozower","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2016.01.062_bib8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.burns.2012.09.020","article-title":"Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey","volume":"39","author":"Fredman","year":"2013","journal-title":"Burns"},{"key":"10.1016\/j.jaad.2016.01.062_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/ajd.12313","article-title":"Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement","volume":"56","author":"Mooney","year":"2015","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2016.01.062_bib10","first-page":"123","article-title":"Adverse effects of topical corticosteroid use","volume":"162","author":"Fisher","year":"1995","journal-title":"West J Med"},{"key":"10.1016\/j.jaad.2016.01.062_bib11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10067-009-1135-x","article-title":"Systemic effects of intra-articular corticosteroids","volume":"28","author":"Habib","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2016.01.062_bib12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.01.062_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","article-title":"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2016.01.062_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical practice. Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.01.062_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","article-title":"High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study","volume":"39","author":"Angeli","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.jaad.2016.01.062_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-6009(91)90139-Q","article-title":"Bone loss in response to long-term glucocorticoid therapy","volume":"8","author":"Locascio","year":"1990","journal-title":"Bone Miner"},{"key":"10.1016\/j.jaad.2016.01.062_bib17","series-title":"Osteoporosis","first-page":"1135","article-title":"Glucocorticoid-induced osteoporosis","author":"Adler","year":"2008"},{"key":"10.1016\/j.jaad.2016.01.062_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaad.2016.01.062_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"Van Staa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2016.01.062_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","article-title":"The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis","volume":"79","author":"Van Staa","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jaad.2016.01.062_bib21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.1780240705","article-title":"Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy","volume":"24","author":"Gluck","year":"1981","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2016.01.062_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","article-title":"Fracture risk with intermittent high-dose oral glucocorticoid therapy","volume":"56","author":"De Vries","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2016.01.062_bib23","series-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","article-title":"Glucocorticoid-induced bone disease","author":"Weinstein","year":"2013"},{"key":"10.1016\/j.jaad.2016.01.062_bib24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1378\/chest.121.5.1456","article-title":"Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens","volume":"121","author":"Dubois","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2016.01.062_bib25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780280402","article-title":"Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases","volume":"28","author":"Dykman","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2016.01.062_bib26","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the\u00a0prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaad.2016.01.062_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bone.2013.05.002","article-title":"Comparison of\u00a0different screening tools (FRAX\u00ae, OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study","volume":"56","author":"Rubin","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.jaad.2016.01.062_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11914-014-0215-2","article-title":"Novel assessment tools for osteoporosis diagnosis and treatment","volume":"12","author":"Gong","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.jaad.2016.01.062_bib29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update","volume":"32","author":"Suzuki","year":"2014","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jaad.2016.01.062_bib30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/acr.22346","article-title":"United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis","volume":"66","author":"Overman","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaad.2016.01.062_bib31","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/jbmr.362","article-title":"Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"26","author":"Hansen","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jaad.2016.01.062_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jaad.2010.05.022","article-title":"Preventing vitamin D toxicity in patients with sarcoidosis","volume":"64","author":"Sage","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.01.062_bib33","first-page":"CD001347","article-title":"Bisphosphonates for steroid induced osteoporosis","volume":"2","author":"Homik","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2016.01.062_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","article-title":"Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats","volume":"60","author":"Patlas","year":"1999","journal-title":"Teratology"},{"key":"10.1016\/j.jaad.2016.01.062_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/taap.1993.1148","article-title":"Effects of the bisphosphonate, alendronate, on parturition in the rat","volume":"121","author":"Minsker","year":"1993","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jaad.2016.01.062_bib36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jaad.2016.01.062_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update","volume":"35","author":"Ruggiero","year":"2009","journal-title":"Aust Endod J"},{"key":"10.1016\/j.jaad.2016.01.062_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2016.01.062_bib39","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.rdc.2012.09.001","article-title":"Safety of bisphosphonates","volume":"38","author":"Orozco","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2016.01.062_bib40","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2016.01.062_bib41","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and\u00a0treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.jaad.2016.01.062_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jaad.2016.01.062_bib43","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2016.01.062_bib44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jaad.2016.01.062_bib45","unstructured":"Food and Drug Administration website. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/DrugSafetyandRiskManagementAdvisoryCommittee\/UCM270958.pdf. Accessed September 9, 2011."},{"key":"10.1016\/j.jaad.2016.01.062_bib46","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/art.10861","article-title":"Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study","volume":"48","author":"Emkey","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2016.01.062_bib47","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s12020-015-0639-1","article-title":"Bisphosphonates and glucocorticoid-induced osteoporosis: cons","volume":"49","author":"Lems","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.jaad.2016.01.062_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ecl.2012.04.004","article-title":"Glucocorticoid-induced osteoporosis and osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jaad.2016.01.062_bib49","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.autrev.2010.06.007","article-title":"Steroid induced osteonecrosis: an analysis of steroid dosing risk","volume":"9","author":"Powell","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2016.01.062_bib50","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/0002-9343(85)90057-9","article-title":"Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus","volume":"79","author":"Zizic","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2016.01.062_bib51","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1056\/NEJM199205283262206","article-title":"Nontraumatic necrosis of bone (osteonecrosis)","volume":"326","author":"Mankin","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaad.2016.01.062_bib52","unstructured":"Nierman L. Pharmacologic use of glucocorticoids. In: Lacroix A, editor. UpToDate. Available at: http:\/\/www.uptodate.com\/contents\/pharmacologic-use-of-glucocorticoids. Accessed September 14, 2016."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216300445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216300445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:39:51Z","timestamp":1759271991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216300445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0190962216300445"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.062","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and management of glucocorticoid-induced side effects: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(16)31128-8","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc. Published by Elsevier. All rights reserved.","name":"copyright","label":"Copyright"}]}}